Komori
Earnings4591RIBOMIC Inc.Pharmaceuticals

First-Quarter Financial Results for the Fiscal Year Ending March 2027 [Japanese GAAP] (Non-consolidated)

The company recorded ¥4 million in business revenue in the first quarter, but operating expenses, including research and development expenses, increased, causing the operating loss to widen from ¥239 million in the same period of the previous year to ¥273 million. The full-year earnings forecast and dividend forecast remain unchanged.

Worth reading
31Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Deterioration
Direction inferred from the company’s description.
Scale
34
¥ millions (widening of operating loss)
Wording
Conditional
How definitive the wording is.

Results for this period

First quarter1 April 2026 to 30 June 2026Non-consolidated (standalone)Japanese GAAP
Net Sales4¥ millionProgress 23.5%
Operating profit-273¥ million
Ordinary income-270¥ million
Net income attributable to owners of the parent-270¥ million

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share¥(4.87)
Financial position at period-end
Total assets2,893¥ million
of which net assets 2,743 ¥ millionEquity ratio 94.8%vs. prior year-end -0.6pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥17 million (YoY +496.7%)
Operating profit¥-1,547 million
Ordinary income¥-1,542 million
Net income¥-1,543 million
Annual Dividend Forecast¥0 → ¥0(0.0%)
Factors Behind Changes in Business Performance

The company recorded no business revenue in the same period of the previous year, whereas it recorded ¥4 million in business revenue in the first quarter under review. It recorded ¥170 million in research and development expenses and ¥107 million in selling, general and administrative expenses as business expenses, resulting in an operating loss of ¥273 million.

Disclosure regarding the going concern assumption

Not applicable.

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Material subsequent eventsOn 3 August 2026, the company reduced the amounts of its stated capital and capital reserves and transferred them to other capital surplus. It then transferred ¥3,188,537 thousand from other capital surplus to retained earnings brought forward to offset the deficit.
Depreciation and amortization¥394 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNo
Issued Shares at Period-End56,572,640
Treasury Shares at Period-End23,824
Results for this period
ItemDetails
Fiscal Period ClassificationFirst quarter
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedNon-consolidated (standalone)
Period Covered1 April 2026 to 30 June 2026
Net Sales¥4 million
Operating profit¥-273 million
Ordinary income¥-270 million
Profit attributable to owners of the parent¥-270 million
Net income per share¥(4.87)
Equity ratioEnd of the current fiscal period 94.8 / End of previous period 95.4
Total assets¥2,893 million
Net assets¥2,743 million
Full-year earnings forecastNet Sales ¥17 million (YoY +496.7%) / Operating profit ¥-1,547 million / Ordinary income ¥-1,542 million / Net income ¥-1,543 million
Annual Dividend Forecast¥0 → ¥0(0.0%)
Depreciation and amortization¥394 thousand
Disclosure regarding the going concern assumptionNot applicable.
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Material subsequent eventsOn 3 August 2026, the company reduced the amounts of its stated capital and capital reserves and transferred them to other capital surplus. It then transferred ¥3,188,537 thousand from other capital surplus to retained earnings brought forward to offset the deficit.
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNo
Issued Shares at Period-End56,572,640
Treasury Shares at Period-End23,824
Factors Behind Changes in Business PerformanceThe company recorded no business revenue in the same period of the previous year, whereas it recorded ¥4 million in business revenue in the first quarter under review. It recorded ¥170 million in research and development expenses and ¥107 million in selling, general and administrative expenses as business expenses, resulting in an operating loss of ¥273 million.
Items this document does not state (15)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogImpairment lossBreakdown of extraordinary income (loss)Changes in the scope of consolidation

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company recorded ¥170 million in research and development expenses and ¥107 million in selling, general and administrative expenses as business expenses.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
First-Quarter Financial Results for the Fiscal Year Ending March 2027 [Japanese GAAP] (Non-consolidated) | RIBOMIC Inc. (4591) timely disclosure | Komori